heparin(redirected from Liquaemin sodium)
Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to Liquaemin sodium: Heparin sodium
1. an acid mucopolysaccharide present in many tissues, especially the liver and lungs, and having potent anticoagulant properties. It also has lipotrophic properties, promoting transfer of fat from blood to the fat depots by activation of the enzyme lipoprotein lipase.
2. a mixture of active principles capable of prolonging blood clotting time, obtained from domestic animals; used in the prophylaxis and treatment of clotting disorders, such as thrombophlebitis, pulmonary embolism, disseminated intravascular coagulation, acute myocardial infarction, or stroke syndrome, and to prevent clotting during extracorporeal circulation, blood transfusion, and blood sampling.
heparin lock a type of intermittent intravenous device for the administration of heparin. It does not require a continuous flow of fluids; the intravenous fluid flow can be disconnected and the heparin lock filled with a heparin solution that maintains patency of the needle.
An anticoagulant principle that is a component of various tissues (especially liver and lung) and mast cells in humans and several mammalian species; its principal and active constituent is a glycosaminoglycan composed of d-glucuronic acid and d-glucosamine, both sulfated, in 1,4-α linkage, of molecular weight between 6,000 and 20,000. In conjunction with a serum protein cofactor (the so-called heparin cofactor), heparin acts as an antithrombin and an antiprothrombin. Synthetic preparations are commonly used in therapeutic anticoagulation. It also enhances activity of "clearing factors" (lipoprotein lipases).
Synonym(s): heparinic acid
An acidic glycosaminoglycan found especially in lung and liver tissue and having the ability to slow the clotting of blood, used as a drug in the treatment of thrombosis.
heparinHematology A sulfated glycosaminoglycan anticoagulant that inhibits activated factors IXa, Xa, XIa, XIIa and thrombin, ↓ local anti-thrombin-III, promoting its inactivation by neutrophil elastase; interaction of heparin with endothelial cells results in displacement of platelet factor 4, which inactivates heparin Indications Thromboembolism, CAD, post acute MI, PTE Monitoring Titrate heparin so that aPTT is 1.5-2.0-fold normal Side effects Hemorrhage, thrombocytopenia, osteoporosis, skin necrosis, alopecia, hypersensitivity, hypoaldosteronism. See Low-molecular weight heparin.
An anticoagulant that is a component of various tissues (especially liver and lung) and mast cells. Its principal active constituent is a glycosaminoglycan composed of d-glucuronic acid and d-glucosamine. In conjunction with a serum protein cofactor (the so-called heparin cofactor), heparin acts as an antithrombin and an antiprothrombin by preventing platelet agglutination and consequent thrombus formation.
heparinA complex polysaccharide organic acid found mainly in lung and liver tissue. Heparin is thought to bind to THROMBIN and antithrombin in plasma thereby assisting in their combination and interfering with the cascade of reactions that end in blood clotting (coagulation). From the Greek hepar , the liver. The drug is on the WHO official list. Heparin is widely used as an anticoagulant under brand names such as Calciparine, Canusal, Hepsal, Monoparin and Multiparin. See also LOW MOLECULAR WEIGHT HEPARIN.
heparina mucopolysaccharide molecule produced in the liver and some white blood-cells that acts as an anticoagulant, inhibiting the transformation of prothrombin to thrombin, a vital stage in BLOOD CLOTTING.
An organic acid that occurs naturally in the body and prevents blood clots. Heparin is also made synthetically and can be given as a treatment when required.